Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,406.43 -588.84 (-0.87%) CMC Crypto 200
1,364.31 +33.70 (+2.53%)
Acarix AB (publ) (7AC.F)
- PR Newswire
Acarix Shares Begin Trading on the US-based OTCQB Market
Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce that the Acarix shares (OTCQB: ACIXF) begin trading today on the OTCQB Market in the US. Acarix´s shares will in parallel to its current Nasdaq First North Growth market listing in Stockholm, be traded with a US ticker symbol and a share price in USD.
- PR Newswire
Acarix announces the initiation of the first US-based clinical workflow evaluation study
Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the initiation of the first US-based clinical study to collect real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States.
- PR Newswire
New Health Economic Analysis Presented at ACC Highlights the Acarix CADScor System's Cost-Effectiveness
Acarix, a leader in acoustic-based Cardiac Diagnostics, is pleased to announce the results from a 2024 American College of Cardiology (ACC) poster presentation by Suzanne Baron, MD, MSc, Director of Interventional Cardiology Research, Massachusetts General Hospital and Faculty at The Baim Institute for Clinical Research, to assess the cost-utility of the CADScor System for the evaluation of coronary artery disease (CAD) in a low-risk patient population presenting to the Emergency Department (ED)
